The development of a nanotechnology enabled anti-viral face mask (NanoMask)

Lead Participant: PHARM 2 FARM LIMITED

Abstract

A survey conducted by the British Medical Association found that half of doctors working in high risk environments do not have access to appropriate face masks. Also, the British Dental Association has lamented the typical UK dentist who can go through 250 face masks per week is now restricted to 100 no matter the practice size. A study by HSE and PHE on the use of PPE in health care settings published on the 27th of March recommended the use of FFP3 but if not available FFP2 and N95 masks can be used. However, there is no certified manufacturing of face masks in the UK and there is only one manufacturer of spunbond and meltblown nonwoven medical fabrics, a material used for FFP2/N95 disposable respirators.

Pharm2Farm (Lead) and Flexotronix (subcontractor) aim to combine their leading nanotechnology capabilities to produce a highly enhanced anti-viral face mask to meet N95/FFP2 and FFP3 specifications.

Lead Participant

Project Cost

Grant Offer

PHARM 2 FARM LIMITED £49,912 £ 49,912
 

Participant

PHARM 2 FARM LIMITED

Publications

10 25 50